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Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an
effective new vaccine is urgently needed. A major barrier to the rational development of
novel TB vaccines is the lack of a validated immune correlate or biomarker of protection.
Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability
to control mycobacterial growth in vitro, and may represent a functional correlate of
protection. However, the biological relevance of any potential correlate can only be
assessed by determining the association with in vivo protection from either a controlled
mycobacterial infection or natural development of TB disease. Our data demonstrate
that the direct MGIA using peripheral blood mononuclear cells (PBMC) is measuring
a biologically relevant response that correlates with protection from in vivo human
BCG infection across two independent cohorts. This is the first report of an MGIA
correlating with in vivo protection in the species-of-interest, humans, and furthermore
on a per-individual as well as per-group basis. Control of mycobacterial growth in the
MGIA is associated with a range of immune parameters measured post-BCG infection in
vivo including the IFN-γ ELISpot response, frequency of PPD-specific IFN-γ or TNF-α
producing CD4+ T cells and frequency of specific sub-populations of polyfunctional
CD4+ T cells. Distinct transcriptomic profiles are associated with good vs. poor
mycobacterial control in the MGIA, with good controllers showing enrichment for gene
sets associated with antigen processing/presentation and the IL-23 pathway, and poor
controllers showing enrichment for hypoxia-related pathways. This study represents an
important step toward biologically validating the direct PBMCMGIA for use in TB vaccine
development and furthermore demonstrates the utility of this assay in determining
relevant immune mechanisms and pathways of protection.
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INTRODUCTION
Tuberculosis (TB) is the leading cause of mortality worldwide
from a single infectious agent, with an estimated 10 million new
cases and 1.5 million deaths in 2018 (1). The high prevalence of
latent Mycobacterium tuberculosis (M.tb) infection, convergence
of the TB and HIV epidemics, emergence of multi-drug resistant
strains of M.tb and the logistics of delivering complex treatment
regimens in endemic countries mean that vaccination is widely
recognized as a critical component of the strategy to control TB
(2). BCG is the only currently available TB vaccine and is widely
used in many parts of the world to protect against severe forms
of TB in infancy (3). However, BCG-induced protection against
pulmonary disease in adults (the most common form of TB) is
extremely variable (4), and there is an urgent need for a new,
more effective vaccine.
A major barrier to the rational development of novel
TB vaccines is the lack of a validated immune correlate or
biomarker of protection. A correlate of protection may be
defined as an immunemarker statistically correlated with vaccine
efficacy (equivalently predictive of vaccine efficacy) that may
or may not be a mechanistic causal agent of protection (5).
Identification of such a correlate would expedite TB vaccine
development, allowing the down-selection of candidates at an
early stage of development and providing a relevant measure of
immunogenicity in phase I clinical trials. The TB vaccine field
has to date focussed largely on identifying T cell signatures of
efficacy, but correlates of protection studies and the outcome
of the MVA85A efficacy trial have cast doubt on the sufficiency
of the cell-mediated response alone to confer protection by
vaccination (6, 7). Mycobacterial growth inhibition assays
(MGIAs) are functional assays that offer an alternative to
measuring predefined individual immune parameters (8). Rather,
they aim to provide an unbiased measure of the ability of whole
blood or cell samples to control mycobacterial growth in vitro,
and as such may represent a correlate of protection without the
need to understand the underlying immune mechanisms.
We have recently worked toward optimizing, standardizing,
and harmonizing the direct MGIA using peripheral blood
mononuclear cells (PBMC) for the evaluation of prophylactic
TB vaccine candidates (9, 10). This assay is adapted from
the methods of Wallis et al. (11) and aims to simplify
the MGIA to maximize reproducibility, applying standardized
reagents and equipment to aid in transferability. The direct
PBMC MGIA has yielded promising results, demonstrating
an ability to detect BCG-induced responses across different
laboratories (10, 12–14). In the absence of an effective vaccine,
identifying a response to BCG vaccination in populations where
it is known to have high efficacy [such as the UK (4)] is
currently a ‘gold standard’ for assessing new models for TB
vaccine evaluation. However, even within such populations BCG-
induced protection is variable and gross comparison by group
central tendencies can be a crude measure when it is unclear
whether such groups truly differ in terms of in vivo protection.
The biological relevance of a potential correlate such as the
MGIA can only be confirmed by demonstrating an association
with in vivo protection from either a controlled human
mycobacterial infection or natural development of TB disease.
Similar assessments are being conducted of the malaria growth
inhibition assay (GIA) in relation to protection from controlled
human malaria infection (CHMI) and immunoepidemiology
studies (15).
While deliberate infection models are in use for other
infectious pathogens (16–19), it is not ethically viable to infect
humans with virulent M.tb. We have previously developed and
described an in vivo human challenge model using intradermal
Mycobacterium bovis BCG vaccination as a surrogate (20–
22). The rationale is that an effective vaccine against M.tb
should also reduce the replication of BCG. BCG represents
a feasible challenge agent, as it causes self-contained limited
infection in immunocompetent humans and is licensed for
human use. Volunteers are infected with intradermal BCG
and 2 weeks later, BCG is quantified from skin biopsies of
the challenge site. This model has demonstrated ability to
detect differences in protective immunity induced by BCG
vaccination in UK adults (20, 21). The aim of the study
presented was to use samples from these human BCG infection
studies to provide biological validation of the direct PBMC
MGIA. We compared in vitro mycobacterial growth in the
MGIA with in vivo growth in skin biopsies from the same
BCG infected human volunteers across different cohorts, and
explored some of the underlying cellular and humoral immune
mechanisms that may be associated with vaccine-induced control
of mycobacterial growth.
METHODS
Human Studies
Samples were taken from two studies of BCG infection in healthy
UK volunteers aged 18–50 years, for whom latent M.tb infection
was excluded by negative ex vivo interferon-gamma ELISpot
responses to ESAT-6 and CFP-10 peptides. All volunteers gave
written informed consent before participation and the trials were
carried out in accordance with the ethical principles set forth
in the Declaration of Helsinki as agreed by the World Medical
Association General Assembly (Washington, 2002), ICH Good
Clinical Practice (GCP) and local regulatory requirements.
Study 1 was approved by the Oxfordshire Research Ethics
Committee A (REC reference 07/Q1604/3) and the full details
including inclusion and exclusion criteria have been described
elsewhere (21). Participants were either BCG-naïve (n = 12)
or historically BCG-vaccinated (n = 12); historically BCG-
vaccinated volunteers were immunized between 8 months and 10
years prior to enrolment with a median time since vaccination of
4 years. A sufficient quantity of cells and autologous serum was
available for MGIA studies from n = 11 volunteers from each
group. All volunteers received intradermal challenge with BCG
(SSI; 0.05mL; diluted in saline to 0.1mL) from a vial containing
2–8× 106 colony-forming units (CFU)/mL, giving a final dose of
∼1–4× 105 CFU into the upper arm (deltoid insertion).
Study 2 (NCT01194180) was approved by the Medicines
and Healthcare Products Regulatory Agency (EudraCT 2010-
018425-19) and the Berkshire Research Ethics Committee (REC
reference 10/H0505/31). Full details are provided elsewhere (20).
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Participants were assigned to group A (BCG-naive; no vaccine
received; n = 11), group B (BCG-naive at baseline; received
intradermal MVA85A, dose 1 × 108 plaque-forming units pfu;
n = 12), group C (BCG-vaccinated at baseline between 8 and
38 years prior to enrolment; median time since vaccination
10 years; n = 13), or group D (BCG-vaccinated at baseline
between 6 and 33 years prior to enrolment; median time since
vaccination 10.5 years; received intradermal MVA85A, dose 1 ×
108 pfu; n = 12) based on their prior BCG vaccination status
and meeting inclusion criteria. A sufficient quantity of cells and
autologous plasma was available for MGIA studies from n =
8 volunteers from group A, n = 11 volunteers from group B,
n = 12 volunteers from group C, and n = 12 volunteers from
groupD. All participants were challenged with a standard vaccine
dose of intradermal BCG (SSI; 0.1mL containing 2–8 × 105
CFU). Those in groups B and D were challenged 4 weeks after
MVA85A vaccination.
For both studies, a punch biopsy was performed at
the challenge site 2 weeks after BCG infection. Freezing,
homogenization and culturing of biopsies as well as
DNA extraction and qPCR methods have been previously
described (20).
Sample Processing
PBMC were isolated from heparinized peripheral blood samples
using density centrifugation. Cells were counted, resuspended in
fetal bovine serum (FBS) and incubated at 4◦C for 20min. An
equal volume of FBS containing 20% dimethylsulfoxide (DMSO)
was then added and cells aliquoted at a concentration of 5–
10 × 106 cells per cryovial, frozen overnight at −80◦C and
transferred to LN2 the following day. Cryopreserved PBMC were
thawed in a water bath at 37◦C until a small amount of frozen
material remained. Samples were gradually added to 10ml RPMI
(containing 10% FBS and 2mM l-glutamine) and centrifuged
at 1,500 rpm for 7min. Supernatants were poured off and cells
resuspended at an approximate concentration of 2–3 × 106 cells
per ml of RPMI (containing 10% fetal calf serum and 2mM l-
glutamine), and 2 µl/ml of 25U benzonase added to each tube.
Cells were rested at 37◦C for 2 h with 5% CO2 before counting
using a CASY Counter (Roche).
Direct PBMC MGIA
3 × 106 PBMC and ∼500 CFU BCG Pasteur in a total volume of
480µl RPMI (containing 2mM l-glutamine and 25mMHEPES),
plus 120 µl autologous serum (Study 1) or plasma (Study 2)
(matched to volunteer and time-point) per well were added to
a 48-well-plate (total volume 600 µl per well). Co-cultures were
incubated at 37◦C for 96 h and then added to 2ml screw-cap
tubes and centrifuged at 12,000 rpm for 10min. During this time,
500 µl sterile water was added to each well to lyse adherent
monocytes. Supernatants were removed from the 2ml screw-
cap tubes, and water from the corresponding well added to the
pellet. Tubes were pulse vortexed and the lysate transferred to
BACTEC MGIT tubes supplemented with PANTA antibiotics
and OADC enrichment broth (Becton Dickinson, UK). Tubes
were placed on the BACTEC 960 machine (Becton Dickinson,
UK) and incubated at 37◦C until the detection of positivity
by fluorescence. On day 0, duplicate direct-to-MGIT viability
control tubes were set up by inoculating supplemented BACTEC
MGIT tubes with the same volume and CFU of mycobacteria
as the samples. The time to positivity (TTP) read-out was
converted to log10 CFU using stock standard curves of TTP
against inoculum volume and CFU. Results are presented as
growth ratio (log10 CFU of sample/log10 CFU of growth control)
to correct for any batch-to-batch variability in inoculum. For
the purposes of the gene expression analysis, BCG-vaccinated
volunteers were classified as “good” or “poor” controllers defined
as having MGIA growth ratio values below or above the group
median, respectively.
Intracellular Cytokine Staining (ICS)
Whole blood was incubated with 1µg/mL αCD28, 1µg/mL
αCD49d (BD Biosciences) and stimulated with 20µg/ml PPD
(SSI, Denmark), 5µg/ml staphylococcal enterotoxin B (Sigma
Aldrich), or no antigen (unstimulated). Samples were incubated
at 37◦C in 5% CO2 for 6 h, 3µg/ml Brefeldin-A (Sigma Aldrich)
was added, and samples were incubated for another 6 h in
a 37◦C water bath. Samples were then treated with 2mM
ethylenediaminetetraacetic acid (Gibco), and red blood cells were
lysed using FACS Lysing solution (BD Biosciences) and samples
were frozen in PBS with 10% DMSO for batched ICS staining.
Frozen samples were thawed, permeabilised and incubated with
antibodies against CD3 (AF700), IFN-γ (PE-Cy7 (eBioscience);
CD4 (APC), CD14 (Pacific blue), TNF-α (PerCP-Cy5.5), and IL-
17 (AF488) (BioLegend); CD8 (APC-H7) (Becton Dickinson)
and IL-2 (PE) (Beckman Coulter). Samples were acquired on
an LSR II flow cytometer (BD Biosciences) and responses
analyzed using FlowJo version 8.8.7 (Tree Star Inc., Ashland,
USA). Cytokines were measured as the frequency of singlet
CD14– CD3+ T cells, CD4+ T cells, and CD8+ T cells. Data
are presented as percentages of cytokine-positive cells minus
responses in unstimulated cells; the gating strategy is shown in
Supplementary Figure 1.
Ex vivo Interferon-Gamma ELISpot
ELISpots were performed using a human IFN-γ ELISpot kit
(capture mAb D1K, Mabtech). Duplicate wells containing 3
× 105 PBMC were stimulated for 18 h with purified protein
derivative (PPD) from M.tb SSI at a concentration of 20µg/ml.
Staphylococcal enterotoxin B (Sigma) was used as a positive
control at a concentration of 10µg/ml, media alone was used
as a negative control and unstimulated PBMCs were used to
measure background IFN-γ production. Results are reported
as spot forming cells (SFC) per million PBMC, calculated by
subtracting the mean count of the unstimulated wells from the
mean count of duplicate PPD-stimulated wells and correcting for
the number of PBMC in the well.
Enzyme-Linked Immunosorbent Assay
(ELISA)
Ninety-six well flat-bottom microtiter plates were coated
overnight with 50 µl per well of BCG SSI (1 × 104 CFU/well).
Samples from Study 2 were prepared by diluting test serum and
positive/negative control serum 1:10 in casein blocking buffer.
The plates were washed 6 times with PBS 0.05% Tween 20,
followed by blocking with 200 µl casein per well for 1 h at
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room temperature. The blocking solution was removed, 50 µl of
sample was added per well (50 µl casein to the negative control
wells), and the plates incubated for 2 h at room temperature.
The plates were then washed 6 times with PBS 0.05% Tween
20. Secondary antibody (goat anti-human γ-chain whole IgG
alkaline phosphatase conjugate) was diluted 1:1,000 in casein,
vortexed and 50 µl added per well. The plates were then
incubated for 1 h at room temperature and washed 6 times
with PBS Tween 20. One hundred microliter of p-nitrophenyl
phosphate (pNPP) development buffer was added to each well
and the plates incubated at room temperature in the dark for
30min. OD405 was read using a Model 550 Microplate Reader
(Bio-Rad, UK).
Gene Expression Microarray Analysis
Gene expression microarrays were performed as previously
described (23). Briefly, 2 × 106 cryopreserved PBMC were
stimulated for 12 h with either R10 medium alone or R10
medium containing 1 × 106 CFU of BCG (SSI). Supernatants
were then removed and the PBMC resuspended in 350 µl
RLT buffer (Qiagen) containing 10 µl/ml β-mercaptoethanol
and frozen at −20◦C. RNA was extracted using an RNeasy
kit (Qiagen) according to the manufacturer’s instructions. RNA
quantity and quality was assessed using a Nanodrop ND-1000
Spectrophotometer and an Agilent Bioanalyzer (Agilent RNA
6000 Nano Kit). Seven hundred fifty nanogram of amplified
complementary RNA was labeled and hybridized to Illumina
Human HT-12 v4 beadchips according to the manufacturer’s
instructions. Beadchips were scanned on an Illumina iScan
machine, and data extracted using the GenomeStudio software.
Transcriptomic analysis was performed in R version 3.5.2
(2018-12-20). Microarray data (GSE58636) were analyzed
for differential expression using R package limma version
3.38.3. To account for between-patient correlations, limma
duplicateCorrelation function was used. A linear model was fit
using limma lmFit function focusing on samples collected at
2 weeks post-infection from group C. Differential expression
between good and poor controllers in the MGIA was evaluated
using moderated t-statistics and the p-values were adjusted
using Benjamini and Hochberg’s (BH) method. Genes with
adjusted p < 0.01 and log2 fold change > 0.5 were identified
as significantly differentially expressed. Genes with low average
expression (normalized intensity < 5) were excluded. The
gene list was collapsed to unique gene identifiers by removing
duplicate probes mapping to gene identifiers when the gene list
was ordered by limma p-value. Gene set enrichment analysis
(GSEA) was performed on the entire list of filtered genes,
ranked by their t-statistic from limma, using “GseaPreranked”
tool in the Java based desktop application of GSEA version
4.0.0 (24). Analysis was completed using the gene sets in
the “C2: curated gene sets” database curated from biomedical
literature and domain experts (http://www.broadinstitute.org/
gsea/msigdb/index.jsp). Gene sets with fewer than 15 genes
or more than 500 genes were excluded. GSEA was run using
remaining gene sets (n = 3,136) with 1,000 permutations of the
gene list.
Statistical Analysis
Statistical analysis of the cellular data was performed using
GraphPad Prism version 7.05 and IBM SPSS version 25.
Normality of data was determined using a Shapiro-Wilk test.
For parametric data with multiple groups, a one-way ANOVA
or repeated-measured ANOVA was conducted followed by
a Dunn’s post-test (comparison of all groups) or Sidak’s
multiple comparisons test (comparison of preselected pairs of
groups). For comparisons between two groups of normally-
distributed data, a t-test or paired t-test was used. For non-
parametric data with multiple groups, a Kruskal-Wallis or
Friedman test was conducted followed by a Dunn’s post-test.
For comparisons between two groups of non-parametric data or
small sample size, a Mann Whitney or Wilcoxon matched-pairs
signed rank test was conducted. A Spearman’s rank correlation
was used to determine associations between two different
measures. Differences were considered statistically significant
at p < 0.05.
RESULTS
Mycobacterial Growth in the MGIA Is
Inhibited in BCG-Vaccinated Compared
With Naïve Volunteers and Correlates With
BCG Recovered From Biopsy Following in
vivo BCG Infection
Samples were taken from a previously-described study of 24
healthy human volunteers (Study 1), half of whom were BCG-
naïve and half of whom were historically BCG-vaccinated.
All volunteers were challenged with intradermal BCG and
BCG load quantified from skin biopsy specimens at the
site of infection 2 weeks later using qPCR and culture
CFU (21). The direct PBMC MGIA was conducted using
cells and serum taken on the day of infection. There was
significantly improved control of mycobacterial growth in the
historically BCG-vaccinated volunteers compared with the naïve
group (Figure 1A, p < 0.0001, Mann Whitney test). This is
consistent with the in vivo result previously reported, where
there was significantly lower BCG recovery from biopsies
of historically BCG-vaccinated compared with BCG-naïve
volunteers using qPCR (Figure 1B, p = 0.02, Mann Whitney
test) but not culture CFU, although the two measures did
correlate (21). There was a significant correlation between
growth in the MGIA and BCG recovered from biopsies in
the BCG-vaccinated group by both qPCR (Figure 1C, r =
0.65, p = 0.03, Spearman’s correlation) and culture CFU
(Figure 1D, r = 0.63, p = 0.04, Spearman’s correlation),
but no associations were observed in the naïve group (data
not shown).
To validate this finding in a second independent cohort,
samples were taken from a previously-described study of 48
healthy human volunteers (Study 2) assigned to groups A
and B (BCG-naïve) or groups C and D (historically BCG-
vaccinated). Groups B and D received the candidate TB vaccine
MVA85A. All volunteers were infected with intradermal BCG
(at 4 weeks post-MVA85A in groups B and D), and skin
Frontiers in Immunology | www.frontiersin.org 4 January 2020 | Volume 10 | Article 2983
Tanner et al. Assessing TB Vaccines in vitro
FIGURE 1 | Mycobacterial growth in the MGIA is inhibited in BCG-vaccinated compared with naïve volunteers and correlates with BCG recovered from biopsy
following in vivo BCG infection (Study 1). Samples were taken from Study 1. n = 24 healthy human volunteers, half of whom were BCG-naïve and half of whom were
historically BCG-vaccinated, were infected with intradermal BCG. The direct PBMC MGIA was conducted on cells and serum taken at the day of infection and the
ratio of mycobacterial growth at the end of the 96 h culture relative to an inoculum control was determined (A). As previously reported, the BCG load was quantified
from skin biopsy specimens at the site of challenge 2 weeks later using PCR (B). The association between mycobacterial growth in the MGIA and BCG recovered
from biopsies in the BCG vaccinated group by both PCR (C) and culture CFU (D) was determined. Bars represent the median values with interquartile range (IQR). For
(A,B) a Mann-Whitney U test was performed, where *p < 0.05 and ****p < 0.0001. For (C,D) a Spearman’s correlation was performed. MGIA growth ratio =
log10(CFU of sample/CFU of control).
biopsies of the challenge site were taken 2 weeks later. BCG
was quantified by qPCR and culture CFU (20). The direct
PBMC MGIA was conducted using cells and serum taken
from all groups at the day of infection. There was significantly
improved control of mycobacterial growth in the historically
BCG-vaccinated group compared with the naïve group or the
MVA85A alone group (group A vs. C and B vs. C) (Figure 2A,
p = 0.04 and p = 0.0063, respectively, one-way ANOVA with
Tukey’s multiple comparisons test). This is consistent with the
in vivo result previously reported, where volunteers with a
history of BCG showed some degree of protective immunity
to intradermal BCG infection using qPCR (but not culture
CFU) (20). BCG-vaccinated volunteers had significantly lower
BCG recovery from biopsy than naïve individuals or those
who received MVA85A only (group A vs. C and B vs. C)
(Figure 2B, p = 0.02 and p = 0.0001, respectively, Kruskal-
Wallis test with Dunn’s multiple comparisons). Individuals
who received BCG followed by MVA85A had significantly
lower BCG recovery from biopsy than those who received
MVA85A only (group B vs. D) (Figure 2A, p = 0.0062, Kruskal-
Wallis test with Dunn’s multiple comparisons). There was a
significant correlation between growth in the MGIA and BCG
recovered from biopsies by qPCRwhen all groups were combined
(Figure 2C, r = 0.45, p = 0.003, Spearman’s correlation) and
in the historically BCG-vaccinated group (group C) alone
(Figure 2D, r = 0.65, p = 0.02, Spearman’s correlation), but
not in groups A, B, or D alone (data not shown). Group C
was our group of interest as these volunteers showed a signal
of protection following both in vivo and in vitro BCG infection,
and BCG is known to be efficacious in the UK population under
study (4).
Frequency of Sub-populations of
Cytokine-Producing CD4+ T Cells Is
Associated With Improved Control of
Mycobacterial Growth in the MGIA
To determine how immune responses stimulated by in vivo BCG
infection relate to control of mycobacterial growth following in
vitro infection, we analyzed a variety of parameters at 2 weeks
post-infection in samples from Study 2. Using whole blood ICS,
significantly more PPD-specific CD4+ T cells producing IFN-
γ were measured in the BCG-vaccinated volunteers (group C)
compared with naïve (group A), MVA85A-vaccinated (group B)
and BCG-vaccinated volunteers boosted with MVA85A (group
D) at 2 weeks post-BCG infection (Figure 3A, p < 0.0001,
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FIGURE 2 | Mycobacterial growth in the MGIA is inhibited in BCG-vaccinated compared with naïve volunteers and correlates with BCG recovered from biopsy
following in vivo BCG infection (Study 2). Samples were taken from Study 2. n = 48 healthy human volunteers were assigned to groups A and B (BCG-naïve) or
groups C and D (historically BCG vaccinated). Groups B and D received the candidate TB vaccine MVA85A. All volunteers were then infected with intradermal BCG.
The direct PBMC MGIA was conducted on cells and plasma taken at the day of infection and the ratio of mycobacterial growth at the end of the 96 h culture relative to
an inoculum control was determined (A). As previously reported, the BCG load was quantified from skin biopsy specimens at the site of challenge 2 weeks later using
PCR (B). The association between mycobacterial growth in the MGIA and BCG recovered from biopsies was determined for all groups combined (C) and for the
BCG-vaccinated group (group C) only (D). Bars represent the median values with IQR. For (A) a Kruskal Wallis test with Dunn’s multiple comparisons was performed
and for (B) a one-way ANOVA with Tukey’s multiple comparisons test was performed, where *p < 0.05, **p < 0.005, and ***p < 0.0005. For (C,D) a Spearman’s
correlation was performed. MGIA growth ratio = log10(CFU of sample/CFU of control).
p = 0.0002, p = 0.01, respectively, one-way ANOVA with
Tukey’s multiple comparisons test). There was a significant
inverse correlation between mycobacterial growth in the MGIA
and PPD-specific CD4+ T cells producing IFN-γ when all
groups were combined (Figure 3B, r = −0.47, p = 0.002,
Spearman’s correlation) and a trend in the historically BCG-
vaccinated group alone (group C), although this was not
statistically significant (Figure 3C, r = −0.51, p = 0.09).
Perhaps unsurprisingly, as the majority of PPD-specific CD4+
T cells produce both IFN-γ and TNF-α simultaneously, similar
patterns were observed for TNF-α with significantly more PPD-
specific CD4+ T cells producing TNF-α measured in the BCG-
vaccinated volunteers (group C) compared with naïve (group A),
MVA85A-vaccinated (group B), and BCG-vaccinated volunteers
boosted with MVA85A (group D) (p < 0.0001, p = 0.0001, p
= 0.01, respectively, one-way ANOVA with Tukey’s multiple
comparisons test; data not shown). There was a significant
inverse correlation between mycobacterial growth in the MGIA
and PPD-specific CD4+ T cells producing TNF-α when all
groups were combined (r = −0.48, p = 0.001, Spearman’s
correlation; data not shown) and a trend in the historically
BCG-vaccinated group alone (group C), although this was
not statistically significant (r = −0.51, p = 0.09; data not
shown). There was a similar pattern between groups for PPD-
specific CD8+ T cells producing IFN-γ, and a significant inverse
correlation with the MGIA when all groups were combined and
a trend in group C alone (r = −0.54, p = 0.0002, and r = −0.56,
p = 0.05, respectively; data not shown). No such associations
were observed in groups A, B, or D when taken alone (data
not shown).
In support of these findings, significantly higher levels
of PPD-specific IFN-γ were detected in BCG-vaccinated
volunteers (group C) compared with naïve (group A)
or MVA85A-vaccinated volunteers (group B) using IFN-
γ ELISpot (Supplementary Figure 2A, p < 0.0001 and
p = 0.0004, respectively, one-way ANOVA with Tukey’s
multiple comparisons test). Responses were also significantly
higher in individuals who received BCG alone compared
with those who received BCG followed by MVA85A
(Supplementary Figure 2A, p = 0.006, one-way ANOVA
with Tukey’s multiple comparisons test). There was a
significant inverse correlation between mycobacterial growth
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FIGURE 3 | Frequency of cytokine-producing specific CD4+ T cells is associated with improved control of mycobacterial growth in the MGIA. Samples were taken
from Study 2. n = 48 healthy human volunteers were assigned to groups A and B (BCG-naïve) or groups C and D (historically BCG vaccinated). Groups B and D
received the candidate TB vaccine MVA85A. All volunteers were then infected with intradermal BCG, and frequency of PPD-specific IFN-γ producing CD4+ T cells
were measured at 2 weeks post-infection using whole blood ICS (A). The direct PBMC MGIA was conducted on cells and serum taken at the day of challenge and
the ratio of mycobacterial growth at the end of the 96 h culture relative to an inoculum control was determined. The association between mycobacterial growth in the
MGIA and the frequency of PPD-specific IFN-γ producing CD4+ T cells was determined for all groups combined (B) and for the BCG-vaccinated group (group C) only
(C). Bars represent the median values with IQR. For (A), a one-way ANOVA with Tukey’s multiple comparisons was performed where *p < 0.05, ***p < 0.0005, and
****p < 0.0001. For (B,C) a Spearman’s correlation was performed. MGIA growth ratio = log10(CFU of sample/CFU of control).
in the MGIA and PPD-specific ELISpot response when
all groups were combined (Supplementary Figure 2B,
r = −0.37, p = 0.02, Spearman’s correlation) and a
trend in the historically BCG-vaccinated group alone
(group C), although this was not statistically significant
(Supplementary Figure 2C, r = −0.49, p = 0.11). No
associations were observed in groups A, B, or D when taken alone
(data not shown).
Considering polyfunctional CD4+ T cells, the dominant
responder population at 2 weeks post-infection for all groups
combined and for historically BCG-vaccinated individuals
alone (group C) was IFN-γ, TNF-α, and IL-2 triple-cytokine
producing cells; while the second most abundant population
was single IFN-γ producers (Figures 4A,B). There were
significant inverse correlations between frequencies of several
subsets and mycobacterial growth in the MGIA when all
groups were combined (Figure 4A). Subsets of cells that
correlated significantly included IFN-γ, TNF-α, IL-2, and
IL-17 quadruple-cytokine producing cells (Figure 4A, r =
−0.44, p = 0.003, Spearman’s correlation) and all permutations
of triple-cytokine producing cells. The strongest association
was with IFN-γ and TNF-α double-cytokine producing cells
(Figure 4A, r = −0.54, p = 0.0002, Spearman’s correlation),
which also represented one of the largest cell populations.
This correlation was also observed in BCG-vaccinated
volunteers alone (group C) (Figure 4B, r = −0.63, p =
0.03, Spearman’s correlation). Other associations that were
replicated in this group were with IFN-γ, IL-2, IL-17 triple-
positive cells (Figure 4B, r = −0.62, p = 0.03, Spearman’s
correlation), TNF-α and IL-2 double-positive cells (Figure 4B,
r = −0.59, p = 0.04, Spearman’s correlation), and TNF-
α single-positive cells (Figure 4B, r = −0.59, p = 0.04,
Spearman’s correlation).
Specific Antibody Responses Are Induced
by BCG Vaccination and IgG Responses
Are Weakly Associated With Control of
Mycobacterial Growth in the MGIA
The level of BCG-specific IgG, IgA, and IgM in the plasma
of volunteers from Study 2 was measured by ELISA at 2
weeks post-BCG infection. There were significantly higher
levels of specific IgG in the plasma from BCG-vaccinated
volunteers (group C) compared with naïve (group A), MVA85A-
vaccinated (group B), or BCG-vaccinated volunteers boosted
with MVA85A (group D) (Figure 5A, p = 0.0002, p = 0.0007,
p = 0.004, respectively, one-way ANOVA with Tukey’s multiple
comparisons test). There were also significantly higher levels
of specific IgA in the plasma from BCG-vaccinated volunteers
compared with who received MVA85A alone (p = 0.02,
Kruskal Wallis test with Dunn’s multiple comparisons, data not
shown). Levels of IgM were low and there were no significant
differences between groups (data not shown). There was a
trend toward an inverse correlation between mycobacterial
growth in the MGIA and level of plasma IgG when all groups
were combined (Figure 5B, r = −0.25, p = 0.11, Spearman’s
correlation), and a statistically significant inverse correlation
between these measures in the BCG-vaccinated group (group C)
alone (Figure 5C, r = −0.64, p = 0.03, Spearman’s correlation),
but not in groups A, B, or D when taken alone (data not shown).
There was a trend toward an inverse correlation between BCG
recovered from biopsies by qPCR and level of plasma IgG when
all groups were combined (r = −0.26, p = 0.07, Spearman’s
correlation) and in the historically BCG-vaccinated group (group
C) alone (r = −0.55, p = 0.07, Spearman’s correlation) but
this was not statistically significant (data not shown). There was
no correlation between MGIA response and levels of IgA or
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FIGURE 4 | Frequency of sub-populations of cytokine-producing specific CD4+ T cells is associated with improved control of mycobacterial growth in the MGIA.
Samples were taken from Study 2. n = 48 healthy human volunteers were assigned to groups A and B (BCG-naïve) or groups C and D (historically BCG vaccinated).
Groups B and D received the candidate TB vaccine MVA85A. All volunteers were then infected with intradermal BCG, and the frequency of PPD-specific CD4+ T cells
producing each of the possible expression profile permutations of the cytokines IFN-γ, TNF-α, IL-2, and IL-17 was determined by flow cytometry using whole blood
samples taken at 2 weeks post-infection. The direct PBMC MGIA was conducted on cells and plasma taken at the day of challenge and the ratio of mycobacterial
growth at the end of the 96 h culture relative to an inoculum control was determined. The association between mycobacterial growth in the MGIA at day of challenge
and frequency of CD4+ T cells producing each profile was determined for all groups combined (A) or for the BCG-vaccinated group (group C) only (B) using
Spearman’s rank correlation, where light blue shading indicates a p < 0.05 and darker blue shading indicates a p < 0.01. Gray bars indicate the mean frequency of
each sub-population of cells with the SEM.
IgM. There was a significant inverse correlation between BCG
recovered from biopsies by qPCR and levels of IgA when all
groups were combined (r = −0.58, p = 0.02) and but not in the
historically BCG-vaccinated group (group C) alone. There were
no associations between BCG recovered from biopsies by qPCR
and levels of IgM (data not shown).
Frontiers in Immunology | www.frontiersin.org 8 January 2020 | Volume 10 | Article 2983
Tanner et al. Assessing TB Vaccines in vitro
FIGURE 5 | Specific IgG ELISA responses are induced by BCG vaccination and are associated with improved control of mycobacterial growth in the MGIA. Samples
were taken from Study 2. n = 48 healthy human volunteers were assigned to groups A and B (BCG-naïve) or groups C and D (historically BCG vaccinated). Groups B
and D received the candidate TB vaccine MVA85A. All volunteers were then infected with intradermal BCG, and BCG-specific IgG responses (A) were measured at 2
weeks post-infection. The direct PBMC MGIA was conducted on cells and plasma taken at the day of challenge and the ratio of mycobacterial growth at the end of
the 96 h culture relative to an inoculum control was determined. The association between mycobacterial growth in the MGIA and the BCG-specific IgG ELISA
response was determined for all groups combined (B) and for the BCG-vaccinated group (group C) only (C). Bars represent the median values with IQR. For (A) a
one-way ANOVA with Tukey’s multiple comparisons was performed where **p < 0.005 and ***p < 0.0005. For (B,C) a Spearman’s correlation was performed. MGIA
growth ratio = log10(CFU of sample/CFU of control).
Distinct Transcriptomic Profiles Are
Associated With Good vs. Poor
Mycobacterial Control in the MGIA
Volunteers from the BCG-vaccinated group (Group C) from
Study 2 (shown in Figure 2A) were classified dichotomously
as “good” or “poor” controllers defined as having MGIA
mycobacterial growth ratio values below or above the group
median, respectively at day of infection. Two volunteers
were excluded due to missing transcriptomic data for either
the unstimulated or BCG-stimulated conditions. Control of
mycobacterial growth was significantly different between the
two sub-groups (p = 0.005, unpaired t-test) with no overlap
in 95% confidence intervals (CI) (95% CI = [0.89, 0.92] and
[0.93, 1.04] for “good” and “poor” controllers, respectively);
data not shown. Time since BCG vaccination and demographic
parameters including age, sex and ethnicity did not differ between
sub-groups (Table 1). Transcriptomic analysis was conducted on
PBMC taken at 2 weeks post-infection. Gene expression was
analyzed using a 2 x 2 factorial design with the interaction
term (BCG stimulated − unstimulated PBMC for good MGIA
controllers) vs. (BCG stimulated − unstimulated PBMC for
poor MGIA controllers). Eighty-two differentially expressed
genes were identified (p < 0.01 and log FC > 0.5); after
removing unannotated and duplicated genes, 76 remained:
49 of which were upregulated in good vs. poor controllers,
and 27 of which were downregulated (Figure 6A). Top genes
upregulated in good vs. poor controllers included IFN-γ, IL-
17F, and IL-24, while those downregulated in good vs. poor
controllers included IFNAR2 and Transgelin (TAGLN). The full
list of significantly differentially expressed genes is provided
in Supplementary Table 1.
Secondary gene-set enrichment analysis (GSEA) using the
C2 curated gene sets and an FDR cut-off of < 0.05, identified
pathways that were unique to each sub-group. The top 50
TABLE 1 | Demographic data for “good” vs. “poor” controllers taken from group
C (historically BCG vaccinated) from Study 2 used in the transcriptomic analysis.
“Good” controllers
(n = 5)
“Poor” controllers
(n = 5)
Age, years 23 (6.80) 23 (8.11)
Time since BCG vaccination,
years
11 (10.42) 10 (10.21)
Sex, male 3 (60%) 2 (40%)
Ethnicity, white British 5 (100%) 5 (100%)
Data are median (SD) or n (%).
pathways were ranked by normalized enrichment score and
categorized according to function and/or overlap in constituent
genes. Good controllers showed enrichment of 135 gene sets
compared with poor controllers; top gene sets included the IL-23
pathway and antigen processing/presentation (Figure 6B). Poor
controllers showed enrichment of 21 gene sets compared with
good controllers which were almost exclusively associated with
hypoxia and glycolysis metabolism (Figure 6B). The full lists
of significantly positively and negatively enriched gene sets are
provided in Supplementary Tables 2, 3 respectively.
DISCUSSION
We have demonstrated a correlation between mycobacterial
growth inhibition in the direct PBMCMGIA and protection from
in vivo BCG infection in humans across two independent studies.
On a group level, MGIA responses mirrored BCG recovery
from biopsy, with BCG-vaccinated volunteers demonstrating
significantly improved protection compared with naïve or
MVA85A-vaccinated volunteers. The BCG-induced MGIA effect
was stronger in Study 1, which may reflect the shorter time since
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FIGURE 6 | Distinct transcriptomic profiles are associated with good vs. poor mycobacterial control in the MGIA. Samples were taken from 10 volunteers assigned to
group C (historically BCG vaccinated) in Study 2. Volunteers were infected with intradermal BCG and gene expression microarray analysis was conducted on PBMC
taken at 2 weeks post-infection. The direct PBMC MGIA was conducted on cells and plasma taken at the day of challenge and the ratio of mycobacterial growth at
the end of the 96 h culture relative to an inoculum control was determined. Volunteers were classified as ‘good’ or “poor” controllers defined as having MGIA
mycobacterial growth values below or above the group median, respectively. Gene expression was analyzed using a 2 × 2 factorial design with the interaction term
(BCG stimulated − unstimulated PBMC for good MGIA controllers) vs. (BCG stimulated − unstimulated PBMC for poor MGIA controllers). Differentially expressed
genes were defined as those with a p < 0.01 and log2 FC > 0.5 and are presented as a heatmap (A). GSEA analysis was conducted to identify biological pathways
that were enriched in “good” vs. “poor” controllers and vice versa using an FDR cut-off of < 0.05. Representative top GSEA pathways for each category are shown
from the top 50 gene sets ranked by normalized enrichment score (nES) (B).
immunization in the historically BCG-vaccinated volunteers in
this study (median of 4 years) compared with those in Study 2
(median of 10 years). However, in Study 2, volunteers who were
historically vaccinated with BCG and boosted with MVA85A
showed significantly lower BCG recovery from biopsy compared
with those who were vaccinated with MVA85A alone, which was
not reflected in the MGIA. This may indicate lower sensitivity
of the MGIA, as may be expected of an in vitro assay that can
onlymodel in vivo complexity to a certain extent. Importantly, we
also observed a correlation between mycobacterial growth in the
MGIA and BCG recovery from biopsy by qPCR or culture CFU at
the level of the individual BCG-vaccinated volunteers. This data
contributes toward the biological validation of the direct PBMC
MGIA as a correlate of protection, and to our knowledge is the
first report of any MGIA correlating with in vivo protection on a
per-individual basis. It is also the first time an MGIA has been
evaluated in relation to in vivo mycobacterial growth using a
controlled human mycobacterial infection.
Although murine studies have previously shown an
association between mycobacterial control in the MGIA
and protection from in vivo M.tb challenge, it was on a per-group
basis, replicating the pattern observed between experimental
groups (25–27). It is not possible to correlate MGIA outcome and
protection on an individual basis in mice or other small animal
models, as animals must be sacrificed to provide bone marrow
macrophages and/or splenocytes for the MGIA. However, in
humans, post-vaccination blood samples can be obtained on
the day of mycobacterial infection, providing matched MGIA
and protection data. Given the variable efficacy of BCG, it is
both more accurate and more stringent to correlate with in vivo
protection on a per-individual basis. Humans also represent the
target species for a TB vaccine candidate. As it is unclear whether
outcomes of preclinical animal models for TB are predictive of
those in humans (28), it is most desirable to develop a correlate
of protection that can be applied to human clinical trials as well
as preclinical studies and bridge between the two. The direct
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MGIA has demonstrated cross-species potential to maximize
utility and comparability (9). One limitation of our studies is
the use of BCG as a surrogate for virulent M.tb in the MGIA
co-culture. However, MGIA outcomes using BCG andM.tb have
previously been shown to strongly correlate (9, 29, 30), and BCG
circumvents the need for biosafety level 3 (BSL3) facilities thus
increasing transferability potential of the assay.
As we were interested in assessing the MGIA as an ex vivo
model of infection, our analysis of associations between the
MGIA response and immune parameters focussed on those
measured at 2 weeks post-infection. Volunteers in this study
were historically BCG-vaccinated and therefore we did not
have the opportunity to measure the immune response to their
initial vaccination. It is possible that immune measures in the
weeks and months following initial vaccination would predict
MGIA and/or in vivo infection outcome; though not possible
to address here, further studies are planned in this regard. In
addition to combining experimental groups, we also measured
correlations with MGIA in our group of interest alone: BCG-
vaccinated volunteers (group C), to ensure that associations were
not artifacts of broad group differences. This group was selected
as BCG is known to be efficacious in the UK population under
study (4), and these volunteers showed a signal of protection in
our in vivo and in vitro infection studies.
Furthermore, 2 weeks is an early time-point to detect an
effector response, as indicated by the very low or undetectable
frequencies of cytokine-producing T cells or specific antibodies
observed in the naïve group, hence group A was not appropriate
for exploring correlates of adaptive immunity. Unfortunately
2 weeks post-infection was the latest time of sampling, and
therefore it was too early to observe measurable adaptive
responses to controlled BCG infection in naïve volunteers. One
might hypothesize that at a later post-infection time-point, these
volunteers would show increased effector and memory T cell
responses but that these may remain inferior to groups C and
D who essentially received a BCG ‘boost’, and that control in
the MGIA may correlate at an individual level within these
groups as currently observed in group C. The group vaccinated
with MVA85A alone (group B) had low levels of protection
from BCG infection in this study (20), and group D (historical
BCG vaccination followed by MVA85A boost) did not show
improved protection over group C (BCG vaccination alone); a
result consistent with the findings of the infant efficacy trial (7).
While group C and group D did not differ in CFU recovered
from biopsy or MGIA responses, group D showed significantly
lower ICS, ELISpot and ELISA responses than group C at 2 weeks
post-infection. However, fold change in these measures between
baseline and post-infection did not differ between these groups,
suggesting some baseline differences between the small number
of volunteers randomized to each group.
We found that the magnitude of the PPD-specific IFN-γ
ELISpot response was inversely associated with mycobacterial
growth in the MGIA in BCG-vaccinated volunteers. A similar
association was previously reported in the same study between
the IFN-γ ELISpot response and CFU recovered from biopsy
following controlled infection (20), suggesting consistency
between parameters contributing to the in vivo and in vitro
models. A central role for IFN-γ in the immune response to TB
is well-established (31–34), and our findings suggest that it may
contribute to bacterial clearance from the site of in vivo infection
and control of mycobacterial growth following in vitro infection,
although it is yet to be determined which cell populations are
contributing to IFN-γ secretion, and cell phenotyping would be
of interest. Previous studies have not identified an association
between specific ELISpot responses and the outcomes of various
MGIAs, including the direct PBMC MGIA (10, 12, 14, 35, 36).
This disparity is likely because those studies compared responses
in samples taken at the same time-point, while we focussed on
associations with post-infection responses. Measuring immune
parameters post-infection permits consideration of re-stimulated
memory responses in historically vaccinated volunteers. Since the
MGIA models an infection, it follows that immune parameters
induced by in vivo stimulation and contributing to control of
mycobacterial replication at the site of BCG administration
may reveal those driving control of mycobacterial growth in
the MGIA.
We also identified associations between frequencies of total
CD4+ T cells producing IFN-γ or TNF-α measured using
ICS and improved control of mycobacterial growth in the
MGIA in BCG-vaccinated volunteers. As previously reported,
the frequency of CD4+ T cells producing IFN-γ or TNF-α also
correlated significantly and negatively with BCG recovered by
qPCR (23), suggesting a shared mechanism of immunity between
the in vivo and in vitro models. Significant inverse associations
were also observed between IFN-γ producing CD8+ T cells
and BCG recovered from biopsy (23) or growth in the MGIA,
suggesting that CD8+ T cells also represent a source of IFN-γ
contributing to protection.
Although IFN-γ is known to be necessary for protection
against TB, it may not be sufficient or reliable as a correlate
of protection (31–34, 37, 38). We therefore considered PPD-
specific polyfunctional CD4+ T cells, and identified IFN-γ, TNF-
α, and IL-2 triple-positive cells as the dominant population
at 2 weeks post-BCG infection. This is consistent with the
findings of Smith et al., who observed these cells to be most
abundant in BCG-vaccinated UK infants at 4 months and 1
year post-vaccination (13), although others have reported a more
heterogeneous profile (39). This may be due to the study of
different populations or the use of antigens other the PPD for
stimulation. We saw significant inverse correlations between
mycobacterial growth in the MGIA and the frequencies of
several subsets of polyfunctional CD4+ T cells including IFN-
γ, TNF-α, and IL-2 triple-positive cells, which is also consistent
with Smith et al. (13). Notably, the strongest association was
with IFN-γ and TNF-α double-cytokine producing cells which
represent an effector memory population (40), supporting our
hypothesis that parameters measured post-infection correlate
with MGIA responses because both are measuring re-stimulated
memory responses.
While others have reported no correlation between MGIA
response and polyfunctional T cells (14, 26), we suggest that this
may be due to the measurement of effector responses soon after
vaccination, while we also captured vaccine-induced memory
responses re-stimulated by in vivo infection. There is currently
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no consensus on whether polyfunctional T cells represent a
marker of protective immunity or TB disease activity (41), but
our data indicate that they may contribute to control of in vivo
and in vitro infection with BCG. A limitation of these studies
is that PPD was used as the stimulant in the ICS studies, while
BCG was used for the in vivo and in vitro infections. Although
stimulation with BCG in the whole blood ICS may facilitate
more direct comparison with the MGIA, we (and others) have
observed similar and corresponding responses to stimulation
with PPD vs. BCG in gene expression profiles, ELISpot, ICS
and ELISA responses (42–45). Furthermore, ICS was conducted
using whole blood, while the MGIA was conducted in the PBMC
compartment. However, we observed very low responses using
cryopreserved PBMC ICS, which is known to be less sensitive
(43, 46, 47), and were unable to detect any associations.
The levels of BCG-specific IgG, and to a lesser extent IgA,
antibodies induced by BCG infection were significantly higher
in the BCG-vaccinated group compared with naïve volunteers
or those receiving MVA85A vaccination. This is consistent
with several previous studies reporting the induction of specific
antibodies following BCG vaccination [(48–51) and recently
reviewed in (52)]. Levels of IgG following BCG infection were
also weakly associated with improved control of mycobacterial
growth in the MGIA in the BCG-vaccinated volunteers and with
in vivo clearance of BCG from the site of infection. Although
humoral immunity has long been neglected in the field due to the
intracellular nature of mycobacteria, there is a growing body of
evidence indicating a role for B cells and antibodies in immunity
from TB ranging from modulation of the T cell response to
antibody-dependent cellular phagocytosis and cytotoxicity (53,
54). O’Shea et al. reported a study of individuals with active TB
disease or latent TB infection (LTBI) in which IgG1 responses
toM.tb-specific antigens correlated with improvedmycobacterial
control in the direct whole blood MGIA (29). Our findings
indicate that antibodies in the autologous serum or plasma added
to the PBMCMGIA may contribute to the overall outcome.
Our transcriptomic analysis revealed distinct patterns of
immune activation in response to specific antigen stimulation
which were associated with differential ability to control
mycobacterial growth in the MGIA in BCG-vaccinated
volunteers. A number of genes of interest were identified
as significantly upregulated following in vivo infection in
“good” compared with “poor” MGIA controllers including
those encoding the cytokines IFN-γ, IL-17F and IL-24 which are
expressed by activated T cells and have been previously associated
with control of TB infection (32, 33, 55, 56). Expression of these
genes was also previously associated with BCG growth in vivo
following BCG infection in these volunteers (23). Applying
GSEA, one of the top gene sets enriched in good controllers was
the IL-23 pathway, which has been implicated in the expression
of the Th17 population and IL-17 response and control of
mycobacterial infection (57–59). Others including antigen
processing/presentation and the proteasome are consistent with
our ELISpot and ICS findings indicating a central role for the
cellular response in controlling mycobacterial growth.
Interestingly, gene sets found to be enriched in poor MGIA
controllers were principally related to hypoxia/the hypoxia
inducible factors (HIF) and associated metabolic reprogramming
toward increased glycolysis. Several studies suggest a protective
role for hypoxia duringM.tb infection (60, 61). However, hypoxia
is amplified as a result of inflammation, and a hypoxia-dominated
expression profile may be indicative of ‘too much’ inflammation,
resulting in suppression of the beneficial T cell response and
consistent with recent reports linking high levels of immune
activation with risk of TB disease (62–64). Alternatively, hypoxia
may be directly limiting the cellular response in these volunteers;
indeed HIF-1α has been shown in some studies to inhibit the
differentiation, proliferation and IFN-γ/IL-2 production of Th1
cells (65–67). The contrasting enrichment patterns may simply
reflect qualitatively or temporally different responses to BCG
infection, and it should be noted that the expression profiles of
cells taken 2 weeks post-challenge are confounded by bacterial
load in those individuals at that time, although it would be
difficult to control for this biologically. While the contradictory
literature on the effect of hypoxia complicates interpretation,
the prominence of such pathways in our analysis supports
further exploration of the role of hypoxia in TB infection and
the potential utility of hypoxia-related host-directed therapies
(61). A limitation of the transcriptomic data is that PBMC
were stimulated with BCG rather than M.tb, although this may
improve comparability with data from our in vivo and in vitro
BCG infections, both of which used BCG.
The direct whole blood MGIA was previously performed
on fresh samples from Study 2 but no differences between
groups were identified and there was no association between
mycobacterial growth and BCG recovery from biopsy by qPCR
or CFU (20). The disparity between this and the current findings
using PBMC may be due to greater inter-assay variability in the
whole blood assay which must be run in real-time compared
with the cryopreserved PBMC assay which was run in just two
batches. Indeed, in a previous comparison of repeated baseline
sampling using whole blood or PBMC, we saw improved inter-
assay reproducibility in the PBMC assay (12). Furthermore, we
have identified an influence of hemoglobin (Hb) and iron on
the direct MGIA (68). While variation in clinical parameters
including Hb levels forms part of the overall picture for clinical
cohort studies and whole blood is applicable in this context
(29, 69), it may confound measures of vaccine-induced control of
mycobacterial growth and reduce sensitivity to detect a vaccine
response (68).
In conclusion, we have demonstrated that the direct PBMC
MGIA correlates with in vivo protection from controlled
mycobacterial infection in humans on a per-individual as well
as per-group basis. Furthermore, we have identified immune
parameters post-in vivo BCG infection that are associated with
improved control in the MGIA post-in vitro BCG infection.
While it has been suggested that control of mycobacterial
growth in the MGIA is driven by trained innate immunity
(14), our cellular and transcriptomic data indicate that the
adaptive immune response, particularly Th1 cells, also strongly
influences outcome in BCG-vaccinated volunteers. The MGIA
is a complex functional assay, likely driven by a combination
of multiple interacting aspects of immunity, which is one of
its advantages over measuring predefined individual parameters.
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Further validation studies are now required for both the
controlled human infection model and the in vitro direct
PBMC MGIA. In particular, it is important to evaluate the
performance of the optimized models in trials of novel TB
vaccine candidates and in different study populations. However,
the data presented offer an indication that the direct PBMC
MGIA is measuring a biologically relevant response and has
the potential to represent a correlate of protection (or a
tool to identify other relevant biomarkers) in the down-
selection of vaccine candidates early in clinical development.
Such a correlate could accelerate optimization and selection of
vaccine candidates and may ultimately accelerate licensure of a
new vaccine.
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Supplementary Figure 1 | Gating strategy for ICS. Stimulated and unstimulated,
fixed, lysed, and stained whole blood samples were acquired on the LSRII
cytometer (BD) and data was analyzed using FlowJo version 8.8.7 (Tree Star Inc.,
Ashland, USA). Singlet, CD3+ and CD14– lymphocytes were chosen (panels
1–3). Panels 5–7 show IFN-γ and TNF-α responses in unstimulated,
PPD-stimulated and SEB-stimulated CD4+ T cells, respectively. Panels 8–10
show IFN-γ and TNF-α responses in unstimulated, PPD-stimulated and
SEB-stimulated CD8+ T cells respectively.
Supplementary Figure 2 | Specific IFN-γ ELISpot responses are associated with
improved control of mycobacterial growth in the MGIA. Samples were taken from
Study 2. n = 48 healthy human volunteers were assigned to groups A and B
(BCG-naïve) or groups C and D (historically BCG vaccinated). Groups B and D
received the candidate TB vaccine MVA85A. All volunteers were then infected with
intradermal BCG, and PPD-specific IFN-γ ELISpot responses were measured at 2
weeks post-infection (A). The association between mycobacterial growth in the
direct PBMC MGIA (conducted on cells and plasma taken at the day of challenge)
and the PPD-specific IFN-γ ELISpot response was determined for all groups
combined (B) and for the BCG-vaccinated group (group C) only (C). Bars
represent the median values with IQR. For (A) a one-way ANOVA with Tukey’s
multiple comparisons test was performed where ∗∗p < 0.005, ∗∗∗p < 0.0005, and
∗∗∗∗p < 0.0001. For (B,C) a Spearman’s correlation was performed. MGIA growth
ratio = log10(CFU of sample/CFU of control).
Supplementary Table 1 | List of significantly differentially expressed genes in
good vs. poor MGIA controllers. Samples were taken from the BCG-vaccinated
group (Group C) from Study 2. Full transcriptomic and MGIA data was available
from n = 10 volunteers, which were classified dichotomously as “good” or “poor”
controllers defined as having MGIA mycobacterial growth ratio values below or
above the group median, respectively, at day of infection. Gene expression profiles
of PBMC taken at 2 weeks post-infection were analyzed using a 2 × 2 factorial
design with the interaction term (BCG stimulated − unstimulated PBMC for good
MGIA controllers) vs. (BCG stimulated − unstimulated PBMC for poor MGIA
controllers). Eighty-two differentially expressed genes were identified (p < 0.01
and log FC > 0.5) and are shown ranked by p-value.
Supplementary Table 2 | List of significantly enriched gene sets in good vs. poor
MGIA controllers. Gene-set enrichment analysis (GSEA) was performed using the
C2 curated gene sets and an FDR cut-off of < 0.05. Good controllers showed
enrichment of 135 gene sets compared with poor controllers, which are shown
here ranked by normalized enrichment score (nES). The top 50 pathways were
categorized according to function and/or overlap in constituent genes. Pathways
shaded in gray could not be meaningfully categorized in this context.
Supplementary Table 3 | List of significantly enriched gene sets in poor vs. good
MGIA controllers. Gene-set enrichment analysis (GSEA) was performed using the
C2 curated gene sets and an FDR cut-off of < 0.05. Poor controllers showed
enrichment of 21 gene sets compared with good controllers, which are shown
here ranked by normalized enrichment score (nES). Pathways were categorized
according to function and/or overlap in constituent genes; those shaded in gray
could not be meaningfully categorized in this context.
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